Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat...

Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help
Combat Swine Flu

CHERRY HILL, N.J., April 29 /PRNewswire-FirstCall/ --Nuvilex, Inc. (OTC
Bulletin Board: NVLX), an emerging healthcare consumer products company, today
announced that it will advance the release of Citroxin to domestic and
international health agencies including hospitals, clinics, and medical
offices as well as other at risk institutions and companies, such as schools
and airlines. Nuvilex has proof of Citroxin's effectiveness in eliminating
swine influenza virus (SIV; H1N1 subtype) and avian influenza virus (AIV; H9N9
subtype) on surface areas but has not yet submitted Citroxin for EPA approval
as an antiviral agent. Citroxin samples will be provided at no cost and the
Company will provide technical assistance. Citroxin is being released early
as the current Swine Flu outbreak requires the best products be deployed to
combat the growing epidemic.

Independent laboratory testing of Citroxin showed a 100% kill rate for the
"big six" bacterial health threats, including E. coli, Listeria, Pseudomonas,
Salmonella, Staphylococcus, Streptococcus, and Black Mold. Citroxin is an EPA
registered germicidal composition (EPA registration number 82723-1) and is
patented in the US and world wide (US 7,439,218 and WIPO 2007/038265 A3).

Interested parties should contact A. Peter Morello III, Ph.D., Director of
Research at Nuvilex via a specially set up email address:
citroxin@nuvilex.com for product information and specifications as well as to
request a sample.

"Given the seriousness of the threat of the spread of swine flu, we believe it
is our duty to push hard to make Citroxin available as soon as possible," said
Martin E. Schmieg, Chairman and CEO of Nuvilex, Inc. "Much of the innovation
in science and technology for combating big problems comes from small
companies such as Nuvilex. Moving our discoveries into the world takes
resources - investment capital, which has all but disappeared from the market
because of the current economic downturn. If Citroxin takes root as
envisioned, demand will outpace our manufacturing capabilities and it will be
necessary for us to seek a commercial partner to move the product quickly into
the marketplace."

Citroxin is a eco-friendly surface cleaner. The Company's viral testing to
date has been led by Sagar M. Goyal, D.V.M., Ph.D. at the University of
Minnesota. Dr. Goyal has investigated the use of Citroxin to treat viral
subtypes of SIV (H1N1). In Dr. Goyal's first experiment, his team evaluated
the ability of Citroxin (dilutions of 1:10 and 1:100) to inhibit the
replication of SIV H1N1 in vitro. Compared to the controls, high
concentrations of Citroxin (1:10 dilution) were found to be virucidal for SIV
growing in MDCK (Madin-Darby canine kidney) cells.

The Company, in conjunction with international based academic researchers, has
also treated H9N9 AIV with Citroxin. In the AIV H9N9 experiments, Citroxin
also served as a better virucidal agent when it received a smaller viral
challenge (1000, 100, and 10 tissue culture infectious dose50, or TCID50, of
virus).

"Although Citroxin is not yet proven to be immunogenic, experiments do suggest
that Citroxin can serve as an effective cleaner or disinfectant for surfaces
that may have come into contact with SIV, AIV, or other types of virus
particles," said Dr. Morello. "We are ready, willing and able to help the
global public health community in combating the swine flu outbreak."

About Nuvilex, Inc.
Nuvilex, formerly eFoodSafety.com, Inc. is an emerging healthcare consumer
products company with a portfolio of aesthetics, dermatology, environmental
and nutraceutical products. The company's focus is on developing, licensing
and commercializing healthcare products that address the health needs of
consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings,
Inc., a diversified skin products technology company serving the fast-growing
body art, aesthetic, cosmetic and skin therapy markets. More information is
available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement
Statements contained in this presentation that are not strictly historical are
"forward-looking" statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities and Exchange Act of
1934. The forward-looking statements are made based on information available
as of the date hereof, and the Company assumes no obligation to update such
forward-looking statements. Forward-looking statements are sometimes
identified by words such as "intends", "anticipates", "believes", "expects",
and "hopes" and involve a number of risks and uncertainties that could cause
the Company's actual results to differ materially from projected results. All
parties are cautioned that such forward-looking statements involve risks and
uncertainties that could cause the Company's actual results to differ
materially from those in these forward-looking statements. Such risks and
uncertainties include but are not limited to demand for the Company's products
and services, the planned share exchange with Freedom2 Holdings, Inc., our
ability to secure additional financing, and other factors that may be more
fully described in reports to shareholders and periodic filings with the
Securities and Exchange Commission.

Investor Relations Contacts:
Blair Barnes
Senior Vice President and Chief Financial Officer
Nuvilex, Inc.
Ph: 856-433-6088
Email: bbarnes@nuvilex.com

Amy Glynn
The Ruth Group
Ph: 646-536-7023
Email: aglynn@theruthgroup.com

Press Contact:
Pat Arcand
Arcand & Madison Public Relations
Ph: 617-576-7777
Email: pat@am-pr.com

SOURCE Nuvilex, Inc.

Investor Relations, Blair Barnes, Senior Vice President and Chief Financial
Officer, Nuvilex, Inc., +1-856-433-6088, bbarnes@nuvilex.com; or Amy Glynn,
The Ruth Group, +1-646-536-7023, aglynn@theruthgroup.com; or Press, Pat
Arcand, Arcand & Madison Public Relations, +1-617-576-7777, pat@am-pr.com